Axita tablet is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograft mouse models.
Recommended Dosing : The recommended starting oral dose of Axitinib is 5 mg twice daily. Administer Axitinib doses approximately 12 hours apart with or without food. Axitinib should be swallowed whole with a glass of water. If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time. Dose Modification Guidelines : Dose increase or reduction is recommended based on individual safety and tolerability. Over the course of treatment, patients who tolerate Axitinib for at least two consecutive weeks with no adverse reactions > Grade 2 (according to the Common Toxicity Criteria for Adverse Events), are normotensive, and are not receiving anti-hypertension medication, may have their dose increased. When a dose increase from 5 mg twice daily is recommended, the Axitinib dose may be increased to 7 mg twice daily, and further to 10 mg twice daily using the same criteria. Over the course of treatment, management of some adverse drug reactions may require temporary interruption or permanent discontinuation and/or dose reduction of Axitinib therapy. If dose reduction from 5 mg twice daily is required, the recommended dose is 3 mg twice daily. If additional dose reduction is required, the recommended dose is 2 mg twice daily.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Selected adverse reactions (all grades) that were reported in < 10% of patients treated with Axita included dizziness (9%), upper abdominal pain (8%), myalgia (7%), dehydration (6%), epistaxis (6%), anemia (4%), hemorrhoids (4%), hematuria (3%), tinnitus (3%), lipase increased (3%), glossodynia (3%), pulmonary embolism (2%), rectal hemorrhage (2%), hemoptysis (2%), deep vein thrombosis (1%), retinal-veinocclusion/thrombosis (1%), polycythemia (1%), and transient ischemic attack (1%).
None
In vitro data indicate that Axita is metabolized primarily by CYP3A4/5 and, to a lesser extent, CYP1A2, CYP2C19, and uridine diphosphate-glucuronosyltransferase (UGT) 1A1. CYP3A4/5 Inhibitors : Co-administration of ketoconazole, a strong inhibitor of CYP3A4/5, increased the plasma exposure of Axita in healthy volunteers. Co-administration of Axita with strong CYP3A4/5 inhibitors should be avoided. Grapefruit or grapefruit juice may also increase Axita plasma concentrations and should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 inhibition potential is recommended. If a strong CYP3A4/5 inhibitor must be co-administered, the Axita dose should be reduced CYP3A4/5 Inducers : Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of Axita in healthy volunteers. Co-administration of Axita with strong CYP3A4/5 inducers (e.g., rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and St. John's wort) should be avoided. Selection of concomitant medication with no or minimal CYP3A4/5 induction potential is recommended. Moderate CYP3A4/5 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, and nafcillin) may also reduce the plasma exposure of Axita and should be avoided if possible.
Hypertension including hypertensive crisis has been observed. Blood pressure should be well-controlled prior to initiating Axita. Monitor for hypertension and treat as needed. For persistent hypertension despite use of anti-hypertensive medications, reduce the Axita dose. Arterial and venous thrombotic events have been observed and can be fatal. Use with caution in patients who are at increased risk for these events. Hemorrhagic events, including fatal events, have been reported. Axita has not been studied in patients with evidence of untreated brain metastasis or recent active gastrointestinal bleeding and should not be used in those patients. Cardiac failure has been observed and can be fatal. Monitor for signs or symptoms of cardiac failure throughout treatment with Axita. Gastrointestinal perforation and fistula, including death, have occurred. Use with caution in patients at risk for gastrointestinal perforation or fistula. Hypothyroidism requiring thyroid hormone replacement has been reported. Monitor thyroid function before initiation of, and periodically throughout, treatment with Axita. Stop Axita at least 24 hours prior to scheduled surgery. Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed. Permanently discontinue Axita if signs or symptoms of RPLS occur. Monitor for proteinuria before initiation of, and periodically throughout, treatment with Axita. For moderate to severe proteinuria, reduce the dose or temporarily interrupt treatment with Axita. Liver enzyme elevation has been observed during treatment with Axita. Monitor ALT, AST and bilirubin before initiation of, and periodically throughout, treatment with Axita. The starting dose of Axita should be decreased if used in patients with moderate hepatic impairment. Axita has not been studied in patients with severe hepatic impairment. Axita can cause fetal harm when administered to a pregnant woman based on its mechanism of action. Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant while receiving Axita.